摘要
目的:比较蔗糖铁注射液和口服右旋糖酐铁分别与促红细胞生成素(EPO)联合应用治疗维持性血液透析(MHD)患者肾性贫血的疗效和安全性。方法:64例MHD的患者,随机分为观察组和对照组,每组32例。观察组每次血液透析时静脉滴注100 mg蔗糖铁,对照组口服右旋糖酐铁100 mg,分别联合EPO治疗8周后,分析两组患者的疗效。结果:治疗8周后观察组Hb、Hct和SF较治疗前明显升高,差异有统计学意义(P<0.05);对照组Hb和Hct升高与治疗前比较,差异无统计学意义(P>0.05);治疗后观察组Hb、Hct和SF明显高于对照组,差异有统计学意义(P<0.05)。观察组的不良反应发生率低于对照组。结论:静脉注射蔗糖铁治疗MHD患者肾性贫血的有效性及安全性均优于口服右旋糖酐铁。
Objective：To compare the efficacy of intravenous iron sucrose and oral iron dextran combined with erythropoietin（EPO） therapy in the maintenance hemodialysis（MHD） patients with renal anemia.Methods：64 MHD patients were randomly divided into observation group and control group,each group of 32 cases.Patients of observation group received 100 mg iron sucrose intravenously during each hemodialysis session,while patients in control group took iron dextran 100 mg tid orally for 8 weeks,and all patients received EPO therapy,the efficacy and safety were analyzed.Results：After 8 weeks of treatment,observation group Hb,HCT and SF were significantly higher than those before treatment,the differences were statistically significant（P〈0.05）;control group Hb and HCT increased,the difference were not statistically significant compared with before treatment（P〉0.05）.After treatment,Hb,HCT and SF of observation group were significantly higher than those of the control group,the difference were statistically significant（P〈0.05）.The incidence rate of adverse reaction in observation group was lower than that in control group.Conclusion：Efficacy and safety of intravenous iron sucrose injection are better than those of oral iron dextran for treating hemodialysis patients with renal anemia.
出处
《华夏医学》
CAS
2016年第1期86-89,共4页
Acta Medicinae Sinica
